12 results on '"Hand–foot skin reaction (HFSR)"'
Search Results
2. 索拉菲尼所致皮肤不良反应的研究进展.
- Author
-
夏静娴, 胡东艳, and 王强
- Abstract
As an oral multi-kinase inhibitor, Sorafenib is widely used for the treatment of advanced renal cell and hepatocellular carcinoma. Skin toxicity is the most common adverse reactions of Sorafenib and may significantly affect the quality of life of patients, resulting in dose reduction or discontinuation of therapy, which will reduce the long-term benefit of the regimen. Hence appropriate recognition of its cutaneous adverse events is of particular importance to ensure proper administration of Sorafenib. This article mainly reviews the cutaneous adverse reactions induced by Sorafenib and corresponding counter measures, as well as the mechanism, clinical manifestations and the influence of adverse reactions on the prognosis of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
- Author
-
Yuma Nonomiya, Takashi Yokokawa, Kazuyoshi Kawakami, Kazuo Kobayashi, Takeshi Aoyama, Tomomi Takiguchi, Takahito Sugisaki, Kenichi Suzuki, Mitsukuni Suenaga, Takeru Wakatsuki, Kensei Yamaguchi, Yoshikazu Sugimoto, and Toshihiro Hama
- Subjects
DRUG side effects ,FOOT ,CANCER hospitals ,HAND ,THERAPEUTICS - Abstract
Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand-foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, more detailed data regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the hands and feet and identify preexisting risk factors for severe HFSR in Japanese patients receiving regorafenib. We retrospectively examined the onset and severity of HFSR on the hands and feet of patients with metastatic colorectal cancer treated with regorafenib from May 2013 to October 2015 in the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. In addition, we examined the possible association between preexisting clinical factors and severe HFSR. Our results showed that no significant difference in the incidence of HFSR of any grade was observed between the hands (71%) and feet (74%) (p=0.63). The incidence of grade 3 HFSR was more frequent on the feet (33%) than on the hands (8%) (p<0.01). The onset of grade 3 HFSR was earlier on the feet than on the hands (p<0.001). No preexisting risk factor was identified. Our findings indicate that severe HFSR was more prevalent on the feet than on the hands, suggesting the need for appropriate screening for early detection and treatment of regorafenib-induced HSFR. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
- Author
-
Koen G. A. M. Hussaarts, Leni van Doorn, Karel Eechoute, Jeffrey Damman, Qiang Fu, Nadia van Doorn, Eric D. Eisenmann, Alice A. Gibson, Esther Oomen-de Hoop, Peter de Bruijn, Sharyn D. Baker, Stijn L. W. Koolen, Teun van Gelder, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen, Alex Sparreboom, and Sander Bins
- Subjects
sorafenib ,probenecid ,hand-foot skin reaction (HFSR) ,pharmacokinetics ,OAT6 ,Pharmacy and materia medica ,RS1-441 - Abstract
Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid decreases sorafenib uptake in skin and might, therefore, decrease sorafenib-induced cutaneous adverse events. Here, the influence of probenecid on sorafenib pharmacokinetics and toxicity was investigated. Pharmacokinetic sampling was performed in 16 patients on steady-state sorafenib treatment at days 1 and 15 of the study. Patients received sorafenib (200–800 mg daily) in combination with probenecid (500 mg two times daily (b.i.d.)) on days 2–15. This study was designed to determine bioequivalence with geometric mean Area under the curve from zero to twelve hours (AUC0–12 h) as primary endpoint. During concomitant probenecid, sorafenib plasma AUC0–12 h decreased by 27% (90% CI: −38% to −14%; P < 0.01). Furthermore, peak and trough levels of sorafenib, as well as sorafenib concentrations in skin, decreased to a similar extent in the presence of probenecid. The metabolic ratio of sorafenib-glucuronide to parent drug increased (+29%) in the presence of probenecid. A decrease in systemic sorafenib concentrations during probenecid administration seems to have influenced cutaneous concentrations. Since sorafenib-glucuronide concentrations increased compared with sorafenib and sorafenib-N-oxide, probenecid may have interrupted enterohepatic circulation of sorafenib by inhibition of the organic anion transporting polypeptides 1B1 (OATP1B1). Sorafenib treatment with probenecid is, therefore, not bioequivalent to sorafenib monotherapy. A clear effect of probenecid on sorafenib toxicity could not be identified in this study.
- Published
- 2020
- Full Text
- View/download PDF
5. Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand–foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta‐analysis.
- Author
-
Zhu, Yi, Zhang, Xiaochen, Lou, Xiaoe, Chen, Min, Luo, Peihua, and He, Qiaojun
- Subjects
- *
ENDOTHELIAL growth factors , *SKIN diseases , *SPORTS medicine , *PATIENT safety , *EMERGENCY medicine - Abstract
Summary: With the use of multikinase inhibitors (MKIs) having emerged in recent years, skin toxicities such as hand–foot skin reaction (HFSR) are primary side effects, and they lack effective prediction methods. Here, we updated a previous systematic review by establishing a meta‐analysis of the risk of developing HFSR among patients receiving MKIs and antivascular endothelial growth factor antibody. Publications from PubMed and abstracts presented at the American Society of Clinical Oncology Annual Meeting up to February 5, 2015, were searched to identify relevant studies, and a total of 236 patients with metastatic tumours in nine trials were included for analysis. In the meta‐analysis, the pooled incidence rates of all‐grade and high‐grade HFSR among patients who received the combination therapy were 56.9% [95% confidence interval (CI), 45%‐71.1%] and 14.3% (95% CI, 9%‐24.2%), respectively, with significant differences observed with MKI monotherapy (P < .05). Further subgroup analysis demonstrated that increasing the dosages of bevacizumab (77.8% vs 51.1%, P = .04) and MKIs (64.3% vs 52.6%, P = .02) significantly increased HFSR incidence. Moreover, combination with chemotherapy exerted a minimal effect on HFSR risk (61% vs 55.3%, P = .5). This updated review and meta‐analysis confirm the increased risk of HFSR incidence due to the use of MKIs and antivascular endothelial growth factor antibody. Thus, using these therapies requires safety standards. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Influence of probenecid on the pharmacokinetics and pharmacodynamics of sorafenib
- Author
-
Hussaarts, K.G.A.M. (Koen), Doorn, L. (Leni) van, Eechoute, K. (Karel), Damman, J. (Jeffrey), Fu, Q. (Qiang), van Doorn, N. (Nadia), Eisenmann, E.D. (Eric D.), Gibson, A.A., Hoop, E.O. (Esther Oomen-De), Bruijn, P.J. (Peter) de, Baker, S.D. (Sharyn), Koolen, S.L.W. (Stijn), Gelder, T. (Teun) van, Leeuwen, R.W.F. (Roelof) van, Mathijssen, A.H.J. (Ron), Sparreboom, A. (Alex), Bins, S. (Sander), Hussaarts, K.G.A.M. (Koen), Doorn, L. (Leni) van, Eechoute, K. (Karel), Damman, J. (Jeffrey), Fu, Q. (Qiang), van Doorn, N. (Nadia), Eisenmann, E.D. (Eric D.), Gibson, A.A., Hoop, E.O. (Esther Oomen-De), Bruijn, P.J. (Peter) de, Baker, S.D. (Sharyn), Koolen, S.L.W. (Stijn), Gelder, T. (Teun) van, Leeuwen, R.W.F. (Roelof) van, Mathijssen, A.H.J. (Ron), Sparreboom, A. (Alex), and Bins, S. (Sander)
- Abstract
Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid decreases sorafenib uptake in skin and might, therefore, decrease sorafenib-induced cutaneous adverse events. Here, the influence of probenecid on sorafenib pharmacokinetics and toxicity was investigated. Pharmacokinetic sampling was performed in 16 patients on steady-state sorafenib treatment at days 1 and 15 of the study. Patients received sorafenib (200–800 mg daily) in combination with probenecid (500 mg two times daily (b.i.d.)) on days 2–15. This study was designed to determine bioequivalence with geometric mean Area under the curve from zero to twelve hours (AUC0–12 h) as primary endpoint. During concomitant probenecid, so
- Published
- 2020
- Full Text
- View/download PDF
7. Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
- Author
-
Peter de Bruijn, Ron H.J. Mathijssen, Esther Oomen-de Hoop, Teun van Gelder, Alice A. Gibson, Nadia van Doorn, Alex Sparreboom, Eric D. Eisenmann, Roelof W F van Leeuwen, Karel Eechoute, Koen G A M Hussaarts, Qiang Fu, Jeffrey Damman, Sharyn D. Baker, Sander Bins, Leni van Doorn, Stijn L.W. Koolen, Medical Oncology, Pathology, and Pharmacy
- Subjects
Sorafenib ,Organic anion transporter 1 ,lcsh:RS1-441 ,Pharmaceutical Science ,Bioequivalence ,Pharmacology ,OAT6 ,urologic and male genital diseases ,Article ,lcsh:Pharmacy and materia medica ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,medicine ,heterocyclic compounds ,Enterohepatic circulation ,neoplasms ,030304 developmental biology ,0303 health sciences ,hand-foot skin reaction (HFSR) ,biology ,business.industry ,Area under the curve ,digestive system diseases ,female genital diseases and pregnancy complications ,Probenecid ,probenecid ,030220 oncology & carcinogenesis ,Toxicity ,biology.protein ,sorafenib ,business ,pharmacokinetics ,medicine.drug - Abstract
Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid decreases sorafenib uptake in skin and might, therefore, decrease sorafenib-induced cutaneous adverse events. Here, the influence of probenecid on sorafenib pharmacokinetics and toxicity was investigated. Pharmacokinetic sampling was performed in 16 patients on steady-state sorafenib treatment at days 1 and 15 of the study. Patients received sorafenib (200&ndash, 800 mg daily) in combination with probenecid (500 mg two times daily (b.i.d.)) on days 2&ndash, 15. This study was designed to determine bioequivalence with geometric mean Area under the curve from zero to twelve hours (AUC0&ndash, 12 h) as primary endpoint. During concomitant probenecid, sorafenib plasma AUC0&ndash, 12 h decreased by 27% (90% CI: &minus, 38% to &minus, 14%, P <, 0.01). Furthermore, peak and trough levels of sorafenib, as well as sorafenib concentrations in skin, decreased to a similar extent in the presence of probenecid. The metabolic ratio of sorafenib-glucuronide to parent drug increased (+29%) in the presence of probenecid. A decrease in systemic sorafenib concentrations during probenecid administration seems to have influenced cutaneous concentrations. Since sorafenib-glucuronide concentrations increased compared with sorafenib and sorafenib-N-oxide, probenecid may have interrupted enterohepatic circulation of sorafenib by inhibition of the organic anion transporting polypeptides 1B1 (OATP1B1). Sorafenib treatment with probenecid is, therefore, not bioequivalent to sorafenib monotherapy. A clear effect of probenecid on sorafenib toxicity could not be identified in this study.
- Published
- 2020
8. Treatment of Hepatocellular Carcinoma Combining Sorafenib and Transarterial Locoregional Therapy: State of the Science.
- Author
-
Weintraub, Joshua L. and Salem, Riad
- Abstract
Abstract: The potential for increased efficacy with combined transarterial chemoembolization and sorafenib is a topic of increased interest to specialists who care for patients with unresectable hepatocellular carcinoma. There is strong scientific rationale for combination therapy: transarterial chemoembolization produces ischemia and stimulates hypoxia-inducible factor–1α, resulting in a local and systemic upregulation of vascular endothelial growth factor (VEGF), which can increase tumor angiogenesis. This upregulation can theoretically be counteracted with the multikinase inhibitor sorafenib, which is thought to act directly on platelet-derived growth factor, Raf kinase, and VEGF receptors. The potential of this approach has not yet been fully realized in clinical trials, and many unanswered questions remain. This review article discusses the state of the science of arterial locoregional therapies and sorafenib. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
9. AVALIAÇÃO DO SÍNDROME MÃO-PÉ NA UTILIZAÇÃO DA CAPECITABINA NO TRATAMENTO DAS DOENTES COM CANCRO DA MAMA AVANÇADO.
- Author
-
Valério, E., Rocha, A., Silva, I., Meneses, C., and Freitas, J.
- Abstract
Copyright of Onco.news is the property of Portuguese Association of Oncology Nursing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2012
10. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands
- Author
-
Takeshi Aoyama, Yoshikazu Sugimoto, Toshihiro Hama, Takahito Sugisaki, Yuma Nonomiya, Kazuyoshi Kawakami, Takashi Yokokawa, Kensei Yamaguchi, Kazuo Kobayashi, Tomomi Takiguchi, Mitsukuni Suenaga, Takeru Wakatsuki, and Kenichi Suzuki
- Subjects
0301 basic medicine ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Side effect ,Drug-Related Side Effects and Adverse Reactions ,Colorectal cancer ,Pyridines ,Antineoplastic Agents ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Japan ,Risk Factors ,Regorafenib ,Medicine ,Humans ,Risk factor ,Neoplasm Metastasis ,Aged ,Retrospective Studies ,Skin ,Aged, 80 and over ,business.industry ,Foot ,Incidence (epidemiology) ,Incidence ,Phenylurea Compounds ,Cancer ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,Hand ,Dermatology ,030104 developmental biology ,Oncology ,chemistry ,Pharmaceutical outpatient clinic ,030220 oncology & carcinogenesis ,Female ,Hand-Foot Syndrome ,business ,Colorectal Neoplasms ,Hand–foot skin reaction (HFSR) ,Foot (unit) - Abstract
Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand‐foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, more detailed data regarding HFSR in terms of onset and sites of susceptibility are unclear. Additionally, the risk factors for regorafenib-induced severe HFSR are unknown. The aim of this study was to compare HFSR between the hands and feet and identify preexisting risk factors for severe HFSR in Japanese patients receiving regorafenib. We retrospectively examined the onset and severity of HFSR on the hands and feet of patients with metastatic colorectal cancer treated with regorafenib from May 2013 to October 2015 in the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. In addition, we examined the possible association between preexisting clinical factors and severe HFSR. Our results showed that no significant difference in the incidence of HFSR of any grade was observed between the hands (71%) and feet (74%) (p = 0.63). The incidence of grade 3 HFSR was more frequent on the feet (33%) than on the hands (8%) (p p
- Published
- 2018
11. Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib.
- Author
-
Hussaarts, Koen G. A. M., van Doorn, Leni, Eechoute, Karel, Damman, Jeffrey, Fu, Qiang, van Doorn, Nadia, Eisenmann, Eric D., Gibson, Alice A., Oomen-de Hoop, Esther, de Bruijn, Peter, Baker, Sharyn D., Koolen, Stijn L. W., van Gelder, Teun, van Leeuwen, Roelof W. F., Mathijssen, Ron H. J., Sparreboom, Alex, and Bins, Sander
- Subjects
- *
ORGANIC anion transporters , *SORAFENIB , *THERAPEUTIC equivalency in drugs , *ENTEROHEPATIC circulation , *PHARMACODYNAMICS , *PHARMACOKINETICS - Abstract
Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid decreases sorafenib uptake in skin and might, therefore, decrease sorafenib-induced cutaneous adverse events. Here, the influence of probenecid on sorafenib pharmacokinetics and toxicity was investigated. Pharmacokinetic sampling was performed in 16 patients on steady-state sorafenib treatment at days 1 and 15 of the study. Patients received sorafenib (200–800 mg daily) in combination with probenecid (500 mg two times daily (b.i.d.)) on days 2–15. This study was designed to determine bioequivalence with geometric mean Area under the curve from zero to twelve hours (AUC0–12 h) as primary endpoint. During concomitant probenecid, sorafenib plasma AUC0–12 h decreased by 27% (90% CI: −38% to −14%; P < 0.01). Furthermore, peak and trough levels of sorafenib, as well as sorafenib concentrations in skin, decreased to a similar extent in the presence of probenecid. The metabolic ratio of sorafenib-glucuronide to parent drug increased (+29%) in the presence of probenecid. A decrease in systemic sorafenib concentrations during probenecid administration seems to have influenced cutaneous concentrations. Since sorafenib-glucuronide concentrations increased compared with sorafenib and sorafenib-N-oxide, probenecid may have interrupted enterohepatic circulation of sorafenib by inhibition of the organic anion transporting polypeptides 1B1 (OATP1B1). Sorafenib treatment with probenecid is, therefore, not bioequivalent to sorafenib monotherapy. A clear effect of probenecid on sorafenib toxicity could not be identified in this study. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Effects of Ascorbyl-2-phosphate Magnesium on Human Keratinocyte Toxicity and Pathological Changes by Sorafenib.
- Author
-
Yamamoto K, Shichiri H, Ishida T, Kaku K, Nishioka T, Kume M, Makimoto H, Nakagawa T, Hirano T, Bito T, Nishigori C, Yano I, and Hirai M
- Subjects
- Apoptosis drug effects, Ascorbic Acid pharmacology, Cell Line, Humans, Niacinamide toxicity, Phosphorylation, RNA, Small Interfering pharmacology, Reactive Oxygen Species metabolism, STAT3 Transcription Factor genetics, STAT3 Transcription Factor metabolism, Signal Transduction drug effects, Skin drug effects, Skin pathology, Sorafenib, Antineoplastic Agents toxicity, Ascorbic Acid analogs & derivatives, Hand-Foot Syndrome prevention & control, Keratinocytes drug effects, Keratinocytes pathology, Magnesium pharmacology, Niacinamide analogs & derivatives, Phenylurea Compounds toxicity
- Abstract
Hand-foot skin reaction is recognized as one of the most common adverse events related to multiple tyrosine kinase inhibitors, but an effective prevention method has not been identified. The chief aim of this study was to find a mechanism-based preventive method for the skin toxicity induced by sorafenib using vitamin C derivatives. The effects of ascorbyl-2-phosphate magnesium (P-VC-Mg) on the molecular and pathological changes induced by sorafenib were investigated in human keratinocyte HaCaT cells. The cell growth inhibition and apoptotic effects of sorafenib were attenuated by P-VC-Mg. Moreover, P-VC-Mg inhibited the decrease of signal transducer and activator of transcription 3 (STAT3) phosphorylation and the expression of apoptosis suppressors treated by sorafenib. HaCaT cells transfected with the STAT3 dominant-negative form (STAT3DN) and STAT3 small interfering RNA (siRNA) combined with P-VC-Mg did not exhibit the attenuation of cell growth inhibition. Interestingly, after exposure to sorafenib in a three dimensional (3D) skin model assay, the basal layer was significantly thickened and the granular and spinous layers became thinner. In contrast, after exposure to sorafenib with P-VC-Mg, the thickness of the basal, granular, and spinous layers was similar to that of the control image. These findings suggest that P-VC-Mg attenuates sorafenib-induced apoptosis and pathological changes in human keratinocyte cells and in the 3D skin model mediated by the maintenance of STAT3 activity.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.